Published in Oncology on October 23, 2015
Design and implementation of microarray gene expression markup language (MAGE-ML). Genome Biol (2002) 16.75
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med (2006) 10.48
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol (2006) 9.16
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol (2012) 4.48
Management of non-small-cell lung cancer: recent developments. Lancet (2013) 3.51
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol (2004) 3.43
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.40
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol (2007) 3.19
Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res (2006) 2.84
The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol (2010) 2.64
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol (2008) 2.53
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol (2005) 2.52
Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol (2004) 2.51
Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer (2005) 2.49
Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA (2004) 2.47
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol (2013) 2.44
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med (2013) 2.38
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology (2011) 2.36
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol (2004) 2.30
Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol (2013) 2.27
Nonapoptotic role for Apaf-1 in the DNA damage checkpoint. Mol Cell (2007) 2.20
Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth. Am J Pathol (2006) 2.19
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg (2004) 2.18
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 2.16
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol (2013) 2.14
Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res (2010) 2.12
Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila) (2008) 2.11
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res (2013) 2.06
Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer. Nat Clin Pract Oncol (2007) 2.05
Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer (2005) 2.04
Treatment outcomes of resected esophageal cancer. Ann Surg (2002) 2.03
Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J (2003) 2.02
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99
Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res (2012) 1.95
Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol (2012) 1.84
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009) 1.83
Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res (2011) 1.83
Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score. Int J Radiat Oncol Biol Phys (2007) 1.83
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol (2011) 1.78
Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer (2007) 1.73
Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg (2005) 1.72
Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys (2010) 1.72
Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst (2012) 1.72
IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype. J Thorac Oncol (2009) 1.72
Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol (2013) 1.72
Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol (2013) 1.71
American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol (2011) 1.71
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol (2010) 1.68
Acute renal infarction: a case series. Clin J Am Soc Nephrol (2012) 1.68
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer (2005) 1.67
Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. Gastrointest Cancer Res (2007) 1.66
Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer (2011) 1.66
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol (2013) 1.66
Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys (2012) 1.65
Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg (2002) 1.64
Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys (2005) 1.63
The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer (2006) 1.63
Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells. Cancer Discov (2012) 1.63
Carcinoid--a comprehensive review. Acta Oncol (2003) 1.63
Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol (2009) 1.61
Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin Cancer Res (2007) 1.59
Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Ann Surg Oncol (2004) 1.58
Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res (2005) 1.57
Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol (2007) 1.56
Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol (2006) 1.55
Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res (2008) 1.53
Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol (2007) 1.52
Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw (2015) 1.52
Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol (2010) 1.52
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res (2011) 1.52
Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol (2006) 1.51
Changing electrolyte and acido-basic profile in HIV-infected patients in the HAART era. Nephron Physiol (2006) 1.51
Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer (2006) 1.50
Gastric cancer: apples will always be apples. J Clin Oncol (2012) 1.49
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol (2011) 1.48
Gastric cancer--an enigmatic and heterogeneous disease. JAMA (2010) 1.48
Involvement of aquaporins in colorectal carcinogenesis. Oncogene (2003) 1.45
Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys (2003) 1.45
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer (2009) 1.45
Telomerase expression in lung preneoplasia and neoplasia. Int J Cancer (2007) 1.45
Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep (2012) 1.45
Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer (2011) 1.43
The area between the curves gets no respect: is it because of the median madness? J Clin Oncol (2007) 1.42
Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut (2012) 1.42
Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther (2006) 1.41
Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer (2005) 1.40
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer (2012) 1.40
Preoperative chemotherapy for localized squamous cell carcinoma of the esophagus? We should go back to the drawing board! Ann Surg Oncol (2012) 1.40
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res (2012) 1.39
Chemotherapy and radiotherapy resistance: complexity, reality, and promise. J Clin Oncol (2008) 1.39
Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. Onkologie (2012) 1.39
Endothelial-cell apoptosis and tumour response to radiotherapy. Lancet Oncol (2004) 1.38
Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res (2005) 1.38